Teva Pharmaceutical Industries ADR
(TEVA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,556,000 | 3,300,000 | 3,226,000 | 2,801,000 | 2,165,000 |
| Receivables | 3,709,000 | 3,059,000 | 3,408,000 | 3,696,000 | 4,529,000 |
| Inventories | 3,179,000 | 3,007,000 | 4,021,000 | 3,833,000 | 3,818,000 |
| Other current assets | 2,380,000 | 2,180,000 | 575,000 | 559,000 | 986,000 |
| TOTAL | $13,946,000 | $12,552,000 | $12,485,000 | $12,051,000 | $12,573,000 |
| Non-Current Assets | |||||
| PPE Net | 4,080,000 | 4,581,000 | 5,750,000 | 5,739,000 | 5,982,000 |
| Intangibles | 19,781,000 | 19,565,000 | 22,564,000 | 23,903,000 | 27,506,000 |
| Other Non-Current Assets | 2,941,000 | 2,628,000 | 2,679,000 | 2,318,000 | 1,606,000 |
| TOTAL | $26,802,000 | $26,774,000 | $30,993,000 | $31,960,000 | $35,094,000 |
| Total Assets | $40,748,000 | $39,326,000 | $43,479,000 | $44,011,000 | $47,666,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,820,000 | 1,781,000 | 1,672,000 | 2,109,000 | 1,426,000 |
| Accounts payable and accrued liabilities | 2,531,000 | 2,203,000 | 2,602,000 | 1,887,000 | 1,686,000 |
| Accrued Expenses | 3,426,000 | 3,416,000 | 3,382,000 | 2,717,000 | 2,771,000 |
| Other current liabilities | 5,325,000 | 4,698,000 | 4,579,000 | 4,755,000 | 5,144,000 |
| TOTAL | $13,456,000 | $12,796,000 | $12,247,000 | $11,469,000 | $11,027,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 14,986,000 | 16,002,000 | 18,161,000 | 19,103,000 | 21,617,000 |
| Other Non-Current Liabilities | 4,089,000 | 4,984,000 | 4,395,000 | 4,347,000 | 2,955,000 |
| TOTAL | $19,378,000 | $21,149,000 | $23,106,000 | $23,945,000 | $25,395,000 |
| Total Liabilities | $32,834,000 | $33,946,000 | $35,353,000 | $35,413,000 | $36,422,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 1,133,839 | 1,121,094 | 1,110,900 | 1,103,330 |
| Common Shares | 58,000 | 58,000 | 57,000 | 57,000 | 57,000 |
| Retained earnings | -13,762,000 | -15,173,000 | -13,534,000 | -12,975,000 | -10,529,000 |
| Other shareholders' equity | -2,387,000 | -3,141,000 | -2,076,000 | -2,044,000 | -1,717,000 |
| TOTAL | $7,914,000 | $5,380,000 | $8,126,000 | $8,598,000 | $11,244,000 |
| Total Liabilities And Equity | $40,748,000 | $39,326,000 | $43,479,000 | $44,011,000 | $47,666,000 |